Breaking News

Samsung BioLogics Receives Additional FDA Approval

Gains third approval for Plant 2 in 26 months

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung BioLogics’ third monoclonal antibody drug substance has been licensed by the U.S. FDA for its second plant. The company has now been approved by the FDA for the manufacture of three commercial Biologics Drug Substances at its second plant in just 26 months since being GMP ready in 2016.    Samsung BioLogics has improved production efficiency with the installation of ten 15,000L bioreactors in a single bio-manufacturing plant. Plant 2 is five times larger and more complicated than Plant...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters